  
 
 
 
 
STATISTICAL ANALYSIS PLAN  
 
Randomized, Parallel Group, Assessor -Blind Study to Evaluate the Oral Mucosal 
Effects in Healthy Adult Smokers Associated with 3 Weeks of Use of Niconovum 
Nicotine Bitartrate 4 mg Mint Lozenge Relative to the [COMPANY_004] Nicorette® Nicotine 
Polacrilex 4 mg Mint Lozenge.  
 
Sponsor Protocol Number:  2016- NBTL -S-005 
Final V1.0, 17 FEB 2017  
 
Clinical Research Organization:  
Inflamax Research Limited  
    [ADDRESS_800944],  
    Mississauga, Ontario, L4W 1A4   CANADA  
 
 
Sponsor:  
Niconovum [LOCATION_003], Inc .  
[ADDRESS_800945]  
Winston -Salem, NC [ZIP_CODE] -2990, [LOCATION_003]  
 
        17 MAY  2017 
 Final  Version 1.0 
 
  
  

 
 
Statistical Analysis Plan   
 
 
Sponsor: Niconovum [LOCATION_003], Inc.  
Sponsor Protocol No. 2016- NBTL -S-005  
 
 
17-May-2017  Final Version 1.0      Page 2 of 53 
Abbreviations  
 
Abbreviations  Term or Definition  
AE Adverse Event  
BMI Body Mass Index  
°C Centigrade  
CS Concomitant Smoker  
DBP Diastolic Blood Pressure  
eCRF  Electronic Case Report Form  
CO Carbon Monoxide  
ECG  Electrocardiogram  
EOS  End of Study  
ePDAT  Electronic Patient Data Acquisition Tablet  
ET Early Termination  
[COMPANY_004]  GlaxoSmithKline  
mITT  Modified Intent -to-Treat  
HIV Human Immunodeficiency Virus  
HLU Heavy Lozenge Use  
ICF Informed Consent Form  
ICH International Conference on Harmonization  
mmol  Millimole  
L Liter 
kg Kilograms  
mm Millimeter  
mmHg  Millimeters of Mercury  
MedDRA  Medical Dictionary for Regulatory Activities  
OMI Oral Mucositis Index  
PP Per protocol  
PT Preferred Term  
SAP Statistical Analysis Plan  
SAE Serious Adverse Event  
SAS Statistical Analysis System  
SBP Systolic Blood Pressure  
SD Standard Deviation  
SOC  System Organ Class  
 
 
Statistical Analysis Plan   
 
 
Sponsor: Niconovum [LOCATION_003], Inc.  
Sponsor Protocol No. 2016- NBTL -S-[ADDRESS_800946] Selection  .................................................................................................................................. 8  
2.4 Stud y procedures .................................................................................................................................. 8  
3 RANDOMIZATION AND BL INDING  ...................................................................................... 11 
3.1 Randomization ..................................................................................................................................... 11 
3.2 Blinding  ................................................................................................................................................. 11 
3.3 Sample Size Calculation  .................................................................................................................... 11 
4 DEFINITION OF ANALYSIS POPULATIONS  .................................................................... 11 
4.1 Randomized Population  ..................................................................................................................... 11 
4.2 Modified Intent- to-Treat (mITT) Population  .................................................................................... 11 
4.3 Per-Protocol (PP) Population ............................................................................................................ 12 
4.4 Heavy Lozenge Use (HLU) Population  ............................................................................................ 12 
4.5 Concomitant Smoker (CS) Population  ............................................................................................ 12 
5 ASSESSMENT AND STUDY  ENDPOINTS  ........................................................................ 12 
 
 
Statistical Analysis Plan   
 
 
Sponsor: Niconovum [LOCATION_003], Inc.  
Sponsor Protocol No. 2016- NBTL -S-[ADDRESS_800947] Disposition and Withdrawals  ............................................................................................. 15 
7.2 Baseline Characteristics  .................................................................................................................... 16 
7.3 Concomitant Medication  .................................................................................................................... 16 
7.4 Medication Administration and Treatment Compliance  .............................................................. 16 
7.5 Primary Analyses  ................................................................................................................................ 17 
7.6 Secondary Analyses  ........................................................................................................................... 18 
7.7 Safety Analyses  ................................................................................................................................... 18 
 
 
Statistical Analysis Plan   
 
 
Sponsor: Niconovum [LOCATION_003], Inc.  
Sponsor Protocol No. 2016- NBTL -S-005  
 
 
17-May-2017  Final Version 1.0      Page 5 of 53 
7.7.1  Adverse Events  ................................................................................................................................... 18 
7.7.2  Physical Examination  ......................................................................................................................... 19 
7.7.3  Vital Signs  ............................................................................................................................................ 19 
7.7.4  12-Lead Electrocardiogram  ............................................................................................................... 19 
7.7.5  Clinical Laboratory  .............................................................................................................................. 19 
7.7.6  Recovery  .............................................................................................................................................. 20 
7.8 Analysis Prior to Study Completion ................................................................................................ 20 
8 TABLES, LISTINGS AND  GRAPHS (TLGS) SHELLS ................................................... 21 
Table 14.1.1 Disposition of Subjects and Analysis Se ts ................................................................................. 22 
Table 14.1.2 Demographics and Baseline Characteristics  ............................................................................ 23 
Table 14.1.3 Summary of Tobacco Use History  .............................................................................................. 24 
Table [IP_ADDRESS] Summary  of Change from Baseline in OMI -20 Total Score  ................................................ 25 
Table [IP_ADDRESS] Summary of Change from Baseline in OMI -20 Total Score  ................................................ 26 
Table [IP_ADDRESS] Summary of Change from Baseline in OMI -20 Total Score  ................................................ 26 
Table [IP_ADDRESS] Summary of Change from Baseline in OMI -20 Total Score  ................................................ 26 
Table [IP_ADDRESS] Summary of Change from Baseline in OMI Erythema Score  .............................................. 26 
Table [IP_ADDRESS] Summary of Change from Baseline in OMI Erythema Score  .............................................. 26 
Table [IP_ADDRESS] Summary of Change from Baseline in OMI Erythema Score  .............................................. 26 
Table [IP_ADDRESS] Summary of Change from Baseline in OMI Erythema Score  .............................................. 26 
Table [IP_ADDRESS] Summary of Change from Baseline in OMI Ulcer Score  ...................................................... 26 
Table [IP_ADDRESS] Summary of Change from Baseline in OMI Ulcer Score  ...................................................... 26 
Table [IP_ADDRESS] Summary of Change from Baseline in OMI Ulcer Score  ...................................................... 26 
Table [IP_ADDRESS] Summary of Change from Baseline in OMI Ulcer Score  ...................................................... 26 
Table [IP_ADDRESS] Overall Summary of Treatment Emergent Adverse Events (TEAEs)  ................................. 27 
Table [IP_ADDRESS] Summary of Treatment Emergent Adverse Events by [CONTACT_177346]  ...................................................................................................................................................... 28 
Table [IP_ADDRESS] Treatment -Emergent Adverse Events by [CONTACT_1196], Preferred Term and 
Maximum Relationship (Modified Intent -to-Treat Population)  ........................................................................ 29 
Table 14.3.4 Summary of Vital Signs  ................................................................................................................ 30 
Table [IP_ADDRESS] Summary of  Overall ECG Interpretation  ................................................................................. 31 
Table [IP_ADDRESS] Summary of ECG Continuous Data Safety Population  ........................................................ 32 
Table [IP_ADDRESS] Summary of Breath carbon monoxide (CO) levels (mITT Population)  ............................... 33 
Table [IP_ADDRESS] Summary of Study Drug Administration .................................................................................. 34 
Table [IP_ADDRESS] Summary of Medication Compliance (mITT Population)  ..................................................... 35 
Table [IP_ADDRESS] Summary of difference in OMI -20 Total Score Between Day 21 and Day 24  ................... 36 
Table [IP_ADDRESS] Summary of difference in OMI Erythema Score Between Day 21 and Day 24  ................ 37 
Table [IP_ADDRESS] Summary of difference in OMI Ulcer Score Between Day 21 and Day 24  ........................ 37 
Listing 16.1.7 Randomization Scheme .............................................................................................................. 38 
 
 
Statistical Analysis Plan   
 
 
Sponsor: Niconovum [LOCATION_003], Inc.  
Sponsor Protocol No. 2016- NBTL -S-[ADDRESS_800948] Disposition and Completion/Early Termination  ......................................................... 39 
Listing 16.2.2 Protocol Deviations  ...................................................................................................................... 40 
Listing [IP_ADDRESS] Demographic Data  ................................................................................................................... 41 
Listing [IP_ADDRESS] Urine Drug Screen and Alcohol Breath Test  ........................................................................ 42 
Listing [IP_ADDRESS] Medical History  ......................................................................................................................... 43 
Listing [IP_ADDRESS] Concomitant Medications  ........................................................................................................ 44 
Listing [IP_ADDRESS] Serology Screen ....................................................................................................................... 45 
Listing [IP_ADDRESS] Pregnancy Tests  ....................................................................................................................... 46 
Listing [IP_ADDRESS] Tobacco Product Use History ................................................................................................. 47 
Listing [IP_ADDRESS] Study Drug Administration  ...................................................................................................... 48 
Listing [IP_ADDRESS] Carbon Monoxide Breath Test  ................................................................................................ 49 
Listing [IP_ADDRESS] Oral Mucositis Index (OMI -20) ................................................................................................ 50 
Listing [IP_ADDRESS] Adverse Events  ......................................................................................................................... 51 
Listing 16.2.8.X Laboratory Measurements: <Laboratory Panel>  ................................................................. 52 
Listing 16.2.9 Vital Signs  ..................................................................................................................................... 53 
 
 
 
 
Statistical Analysis Plan   
 
 
Sponsor: Niconovum [LOCATION_003], Inc.  
Sponsor Protocol No. 2016- NBTL -S-005  
 
 
17-May-2017  Final Version 1.0      Page 7 of 53 
1 INTRODUCTION TO THE STATISTICAL ANALYSIS PLAN  
This Statistical Analysis Plan (SAP) provides a thorough description of statistical analysis methods and presentation of the study data from the clinical trial described in Study Protocol 
2016- NBTL -S-005: 
 
 “Randomized, Parallel Group, Assessor -Blind Study  to Evaluate the Oral Mucosal Effects 
in Healthy Adult Smokers Associated with 3 Weeks of Use of Niconovum Nicotine 
Bitartrate 4 mg Mint Lozenge Relative to the [COMPANY_004] Nicorette® Nicotine Polacrilex 4 mg 
Mint Lozenge”.  
 This SAP is based on the final protocol  dated 27 February  2017 ( Final  1.0).  
 The SAP  includes details of data handling procedures and statistical methodology.   
No interim analysis is planned for this study.  
 The final statistical analysis will proceed according to the SAP approved by [CONTACT_604783] , 
Inc. as well as by [CONTACT_604784]. There are no deviations of analysis methods from the 
protocol. Any deviations in final analysis from this SAP will be documented in the final Study 
Summary Report . 
 Tables and Listings are numbered following the International Conference on Harmonization 
(ICH) structure E3 “Structure and Content of Clinical Study Report”.  All summary tables  and 
listings  will be generat ed using SAS®  Version 9.2 or higher. Tables , listings  and graphs  will be 
delivered to the Sponsor as .rtf file s. 
 
The following documents were reviewed in preparation of the SAP: 
• Electronic Case Report Form (eCRF) Final  Version 1.0 dated on 20MAR2017 
• Data Management Plan Final Version 1.0 dated on 03APR2017 
• eCRF Completion Guidelines Final Version 1.0 dated on  20MAR2017  
• Codelist Details Final Version dated on  30MAR2017 
  
 
 
Statistical Analysis Plan   
 
 
Sponsor: Niconovum [LOCATION_003], Inc.  
Sponsor Protocol No. 2016- NBTL -S-005  
 
 
17-May-2017  Final Version 1.0      Page 8 of 53 
2 INTRODUCTION TO THE STUDY  
2.1 Overview of Study  
This will be a single -center, ambulatory, randomized, parallel group, assessor -blind, 3- week, 
safety study in healthy adults motivated to quit smoking. Subjects will be instructed to quit 
smoking (starting Day 1) and use 9 - 20 lozenges per day for 3 weeks.  Subjects will be 
randomized 1:1 to treatment with Nicotine Bitartrate 4 mg mint lozenge (test product) or 
Nicorette® [Nicotine Polacrilex] 4 mg mint lozenge (reference product).  In each treatment group a minimum of 10% of the study population will be smokers of ≥ 30 cigarettes/day, and a minimum of 40% of the study population will be smokers of 20 - 29 cigarettes/day.  
Randomization will be stratified by [CONTACT_604785].    
2.2 Study Objectives 
2.2.1  Primary  
• To assess the oral mucosal health associated with [ADDRESS_800949], Nicotine 
Bitartrate 4 mg mint lozenge (Niconovum), relative to a reference product, Nicorette® 
[Nicotine Polacrilex] 4 mg mint lozenge ([COMPANY_004]), in healthy adult smokers motivated to quit smoking.  
2.2.2  Secondary  
• To evaluate the safety and tolerability of Nicotine Bitartrate 4 mg mint lozenge and 
Nicorette® [Nicotine Polacrilex] [ADDRESS_800950] signed written 
informed consent and satisfy the study inclusion/exclusion criteria per protocol will be selected 
to participate in this study. The Day [ADDRESS_800951] seven study visits, including the Screening Visit , as summarized in Table 1 
‘Schedule of Study Events ’. At the Screening Visit, safety assessments , evaluation of oral health  
by a dental hygienist, carbon monoxide assessment  and other procedures  will be performed to 
determine eligibility  of potential subjects to enroll in the study, and informed consent forms will 
be obtained prior to any screening procedures.  
 
At the Test Visit Day 0 (baseline), eligibility will be reconfirmed and subjects will be enrolled. 
Evaluation of oral health wil l be conducted by a dental hygienist, and recorded as baseline 
 
 
Statistical Analysis Plan   
 
 
Sponsor: Niconovum [LOCATION_003], Inc.  
Sponsor Protocol No. 2016- NBTL -S-005  
 
 
17-May-2017  Final Version 1.0      Page 9 of 53 
score. Subjects will receive a Study Kit consisting of individual Daily Packs each containing 20 
lozenges on Day 0 and subsequent lozenge dispensing will occur on Days 7 and 14.  Subjects 
will b e informed that daily use is permitted to vary between 9 - 20 lozenges per day, and be 
instructed to use lozenges from only one Daily Pack per day.  At baseline (Day 0), subjects will 
each receive Inflamax’s ePDAT® (Electronic Patient Data Acquisition Tablet) system for the 
daily (at least once daily) recording of their daily lozenge usage.  In addition, subjects will also be 
instructed to indicate on the ePDAT® system (once daily) if they have experienced any change 
in health and/or if any concomitant medication was taken or how many (if any) cigarettes were 
smoked.  Furthermore, subjects will also be given a take- home journal on Day [ADDRESS_800952]/describe, at their own discretion, further detail of any changes in health experienced and concomitant smoking/medication.   
 
On all other visits (Days 3, 7, 14, [ADDRESS_800953] -dosing), oral examinations by a blinded 
dental assessor (dental hygienist, dentist or dental surgeon) will be conducted using the Oral 
Mucositis Index (OMI -20) scale.  In addition, the blinded assessor will identify any new areas of 
leukoplakia, erythroplakia or ulceration over 1 cm in diameter, or other oral lesions that cannot be diagnosed by [CONTACT_604786].  Vital signs, adve rse events, and 
concomitant medications will be collected at each visit by [CONTACT_604787]. Clinical laboratory evaluations and electrocardiograms will be conducted at selected visit s.  
 Subjects will be discharged from the study following completion of study procedures and all 
appropriate safety assessments, at the Investigator’s discretion.  
 
  
 
 
Statistical Analysis Plan   
 
 
Sponsor: Niconovum [LOCATION_003], Inc.  
Sponsor Protocol No. 2016- NBTL -S-005  
 
 
17-May-2017  Final Version 1.0      Page 10 of 53 
Table 1: Schedule of Study Events  
 
1 Changes in health (adverse events), any concomitant medication used and smoking history will be monitored through the ePDAT® system as per subject entries and take- home journals 
throughout the study duration.  
[ADDRESS_800954] at Screening; urine pregnancy test at Check -in of Day [ADDRESS_800955] lozenge the next morning (i.e., Quit day = Day 1).  
9 Assessment of lozenge use will be collected through the ePDAT® system (once daily) and take- home journals.  
[ADDRESS_800956] or dental surgeon. Each lesion will be biopsied once.  
11 Clinically significant abnormalities at Study Day 21 will be re -evaluated at Day 24 for recovery.    Assessment  Screening 
Visit  Baseline  Treatment  Follow -up 
Day -21 to 
Day -1 Day 0  Day 3  Day 7  Day 14  Day 21  Day 24  
Informed consent  X       
Inclusion/Exclusion criteria  X X      
Demographics  X       
Height, weight and determine 
BMI  X       
Medical History  X X      
Smoking History1 X       
Physical examination  X       
Oral Health Assessment2 X X      
ePDAT® Instruction   X      
Pregnancy test(females)[ADDRESS_800957]  X X      
Urinalysis  X X  X  X  
Vital signs4 X X X X X X X11 
Electrocardiogram5 X   X  X X5 
Clinical laboratory 
evaluations6 X X  X  X X11 
Concomitant medication1 X X X X X X X 
Carbon monoxide 
assessment7  X X X X X  
Oral assessment (OMI -20)  X X X X X X 
Study drug dispensing   X8  X X   
Recording  of lozenge use9   X X X X  
Adverse event monitoring1  X X X X X X 
Biopsy10   X X X X X 
                             
                                                                                           
 
 
Statistical Analysis Plan   
 
 
Sponsor: Niconovum [LOCATION_003], Inc.  
Sponsor Protocol No. 2016- NBTL -S-005  
 
 
17-May-2017  Final Version 1.0      Page 11 of 53 
  
3 Randomization and Blinding  
3.1 Randomization  
Subjects will be randomized in a 1:1 ratio to receive either Nicotine Bitartrate 4 mg mint lozenge 
(Test Product) or Nicorette® 4 mg mint lozenge (Reference Product). A total of  100 subjects (50 
in each group) will be randomized in the study  at a single study site. Randomization will be 
stratified by [CONTACT_604788] a minimum of 10% of the subjects will be smokers of ≥ 30 cigarettes/day, and a minimum of 40% of the subjects will be smokers of 
20 - 29 cigarettes/ day.
 
3.2 Blinding 
The study staff conducting the oral assessment (dentist or dental hygienist) shall be blinded to the subject’s treatment arm. These staff will not be present  during distribution or use of  
lozenges. Subjects will be instructed not to show their investigational product to the oral assessors. In addition, subject s and blinded assessor will be instructed to not discuss the 
lozenge type (study arm) that the subject is using, and a separate study team member will 
manage all distribution and collection of study medication to assure assessor blinding is 
maintained. Furthermore, the blinded assessor will input OMI -[ADDRESS_800958] Nicotine Bitartrate 4 mg mint lozenge (Niconovum), relative to a reference product, 
Nicorette® [Nicotine Polacrilex] 4 mg mint lozenge ([COMPANY_004]). A total of [ADDRESS_800959] of all subjects who are randomized to the Treatment.  
4.2 Modified Intent-to -Treat (mITT) Population 
The mITT population will include all subjects who were randomized and used at least 1 lozenge. This will be the main population for analysis.  
                             
                                                                                           
 
 
Statistical Analysis Plan   
 
 
Sponsor: Niconovum [LOCATION_003], Inc.  
Sponsor Protocol No. 2016- NBTL -S-005  
 
 
17-May-2017  Final Version 1.0      Page 12 of 53 
4.3 Per-Protocol (PP) Population 
The per -protocol population will be a subset of the mITT population and will consist of subjects 
who complete the study without any major protocol deviations, as determined by [CONTACT_604789].  
Major protocol deviations include:  
• CO levels exceeding 10 ppm at one or more study day visit (CO is expected to be > 10 
ppm on Day 0)  
• Use of < 9 or > 20 lozenges/day on more than 2 study days  
 
4.4 Heavy Lozenge Use (HLU) Population 
The heavy lozenge use population will be a subset of the mITT population and will consist of subjects who use on average 15 or more lozenges per day (irrespective of completion of the 
study) . 
4.5 Concomitant Smoker (CS) Population 
The concomitant smoker population will be a subset of the mITT population and will consist of subjects who either admit smoking during the study or who have a CO > 10 ppm at any study 
day excluding Day 0 or Day 24 that cannot otherwise be explained.  
5 ASSESSMENT AND STUDY ENDPOINTS  
5.1 Oral Safety Assessment  
Oral examinations will be conducted using a 20 Item Oral Mucositis Index (OMI -20), a validated 
scale developed to measure several indications of oral mucositis. Assessors will be licensed dental professionals (dental hygienists or dentists). These selected dental professionals will be 
trained in the assessment protocol and the OMI -[ADDRESS_800960] has been randomized to receive. 
OMI-20 will be assessed on Days 0, 3, 7, 14, 21 and Day 24 (post dose) visits.  
5.2 Primary Endpoint 
OMI-20 Total score change from baseline (Day 0) at each study visit (Days 3, 7, 14 and 21) in 
the Modified- Intent -to-Treat (mITT) population.   
 
                             
                                                                                           
 
 
Statistical Analysis Plan   
 
 
Sponsor: Niconovum [LOCATION_003], Inc.  
Sponsor Protocol No. 2016- NBTL -S-005  
 
 
17-May-2017  Final Version 1.0      Page 13 of 53 
5.3 Secondary  Endpoints 
• OMI-20 Total score change from baseline (Day 0) at each study visit (Days 3, 7, 14 and 
21) in PP population, heavy lozenge use population and concomitant smoker population.  
• OMI-20 Erythema subscore change from baseline at each study visit (Days 3, 7, 14 and 
21) in all populations.  
• OMI-20 Ulcer subscore change from baseline at each study visit (Days 3, 7, 14 and 21)  
in all populations . 
5.4 Safety  Endpoints 
• Clinical laboratory assessments (clinical chemistry; hematology; serology; urinalysis)  
• Vital signs  
• 12-lead Electrocardiogram (ECG)  
• Analysis of biopsied materials (if any) and adverse events  
5.5 Other Safety Endpoints 
• OMI-20 Total score Day 24 versus Day 21  
• OMI-20 Erythema score Day 24 versus Day 21 
• OMI-20 Ulcer score Day 24 versus Day 21  
• Safety endpoints Day [ADDRESS_800961] summary  statistics that will be calculated for quantitative and qualitative variables 
are: 
Quantitative:  number of subjects, mean, median, standard deviation (SD), minimum 
and maximum of the raw data  
Qualitative:  number of subjects, number of missing data (if not zero), absolute and 
relative frequencies per class   
 
                             
                                                                                           
 
 
Statistical Analysis Plan   
 
 
Sponsor: Niconovum [LOCATION_003], Inc.  
Sponsor Protocol No. 2016- NBTL -S-005  
 
 
17-May-2017  Final Version 1.0      Page 14 of 53 
6.2 Reporting Precision 
Summary statistics will be presented to the following degree of precision: 
Statistics  Degree of Precision  
Mean (of all kinds), Median ,  
 One more decimal place than the raw data  
Standard deviation  Two more decimal places than the raw data  
 
Minimum, Maximum  The same number of decimal places as the raw 
data 
 
Percent  One decimal place  
 
 
6.3 Commonly Used Algorithms 
6.3.1  Duration  of Adverse Events  
When adverse events (AEs) have incomplete start dates and times, no imputation will be 
performed. Duration will be calculated for AEs that resolve as the difference between the resolution date and time and onset date and time and will be expressed in days, hours and 
minutes. If either time is missing, duration will be expressed in days. Duration will only be calculated when both dates are complete.  
6.4 Data Handling Rules  
The following section describes the rules for handling data, including  the definitions of derived 
variables  and handling missing data . 
6.4.1  Derived V ariables  
• Age is  calculated in years  after rounding  down as follows:  
Year  of age = (Date  [in days  format] informed consent  signed  - Date  [in days  format]  of 
birth)  / 365.25  
 
6.4.2  Missing Data 
Any missing values for the study endpoints  will not be replaced and the observed data will be 
used for the endpoint  analysis. No data interpolation or extrapolation will be carried out if there 
is missing data.  
                             
                                                                                           
 
 
Statistical Analysis Plan   
 
 
Sponsor: Niconovum [LOCATION_003], Inc.  
Sponsor Protocol No. 2016- NBTL -S-[ADDRESS_800962] Disposition and Withdrawals 
The following frequencies (number and percent) will be displayed by [CONTACT_604790] : 
• Subjects in the Randomized Population (number only)  
• Subjects in the Modified Intent -to-Treat Population (number only)  
• Subjects in the Per -Protocol Population (number only)  
• Subjects in the Heavy Lozenge Use Population  (number only)  
• Subjects in the Concomitant Smoker Population (number only)  
• Subjects who completed the study  (number and percent)  
• Subjects who discontinued early, as well as reasons for subject discontinuat ion (number 
and percent)  
The denominators for the percent calculations will be the number of subjects in the Randomized 
population per treatment or overall . 
Subjects’ completion/discontinuation status wi ll be listed by [CONTACT_604791], date of enrollment, date of completion/early discontinuation, date of last 
contact  [INVESTIGATOR_1238], for those who discontinued early, the specific reason  for discontinuation.  
All deviations related to study inclusion or exclusion criteria, conduct of the trial, subject 
compliance or subject concomitant smoking  will be listed. The justification of majo r/minor on 
protocol deviations may be determined among the Principal Investigator [INVESTIGATOR_604778], and the Sponsor . 
 
                             
                                                                                           
 
 
Statistical Analysis Plan   
 
 
Sponsor: Niconovum [LOCATION_003], Inc.  
Sponsor Protocol No. 2016- NBTL -S-005  
 
 
17-May-2017  Final Version 1.0      Page 16 of 53 
7.2 Baseline Characteristics 
Demographics (age, sex, race, ethnicity, weight, height and BMI) will be summarized using 
descriptive statistics (number of subjects, mean, standard deviation, minim um, median and 
maximum for quantitative variables, and number of subjects and percent of subjects for 
qualitative variables) by [CONTACT_10605] m ITT population. No formal 
statistical comparison between treatment groups will be performed . Together with the informed 
consent  date, the above information will be listed by [CONTACT_604792].  
Other  baseline characteristics will be listed by [CONTACT_604793]:  
• Medical/medication history  
• History of Tobacco/nicotine product use/consumption and smoking/vapi[INVESTIGATOR_285816]  
• Pregnancies (female only)  
• Urine drug screen and alcohol breathalyzer test  
The history of tobacco/nicotine production use/consumption and smoking/vapi[INVESTIGATOR_604779] , subject, substance name, start date of use, end date of use, ongoing use, 
frequency of use, amount used (amount/ unit/frequency) .. A summary table will be produced by 
[CONTACT_604794]. The summary statistics will 
also report the number of subjects who reported using the product at each frequency level ( less 
than 20 cig arettes per day , 20 – 29 per day, and more than 30 per day) within treatment  group 
and overall.  
7.3 Concomitant Medication 
The use of concomitant medications will be requested in the ePDAT® system, and subjects will 
be able to indicate whether any concomitant medication was used during the study.  The full 
description of the concomitant medication usage will be recorded in the take- home journals 
provided to the subjects, indicating the following information (as possible):  Name [CONTACT_61144], 
Reason for use , Frequency of use , Route of administration , Dose , and Start date and Stop date 
(where applicable). The above information will listed by [CONTACT_3148]. No summary table will be output.  
7.[ADDRESS_800963] lozenge use 
through Inflamax’s ePDAT take- home tablet once daily. Number of used lozenges since last  
visit will be calculated as deduction of the dispensed lozenge number of last visit from the 
                             
                                                                                           
 
 
Statistical Analysis Plan   
 
 
Sponsor: Niconovum [LOCATION_003], Inc.  
Sponsor Protocol No. 2016- NBTL -S-005  
 
 
17-May-2017  Final Version 1.0      Page 17 of 53 
returned lozenge number of this visit. Average number of lozenges used per day will be also 
calculated as di viding total number of used lozenges by [CONTACT_604795] .  
Treatment compliance will be determined by [CONTACT_604796] (CO) and average 
number of lozenges.  
Breath carbon monoxide (CO)  levels will be presented by [CONTACT_604797]. Based on level of CO, subject s will be divided  as compliant 
subjects (CO<=10 ppm  at all study day visits) and non- compliant subjects (CO>10  ppm at any 
study day visit ). Breath carbon monoxide (CO)  levels  will be listed by [CONTACT_3148], together with 
visit and date. In the listing, non -compliance will be flagged.  For those who comply with the 
requirements, CO level will be summarized with descriptive statistics (n umber , mean, SD, 
minimum, median and maximum) by [CONTACT_10659]. T he number of subjects and 
percentage will be calculated based on whether the CO level is higher or lower  than 10 ppm. 
Number of lozenges will also be used to determine  compliance. Lozenge use of less than 9 or 
more than 20 for more  than 2 study days will be treated as a major violation of compliance and 
qualifies subjects  as non -compliant.  
The a verage number of used lozenges will be summarized with descriptive statistics (n, mean, 
SD, minimum, median and maximum) by [CONTACT_604798] . 
The number of subjects and percentage will also be calculated based on compliance.  
Compliance or non- compliance will be tabulated by [CONTACT_604799].  
Medication administration will be listed by [CONTACT_3148], including subject number, visit, visit date, the number of dispensed lozenges, the number of returned lozenges, the number of used 
lozenges and average number of lozenges used per day . Non-compliance on specific day (s) will 
be flagged, and total number of non- compliant days will be listed.  
 
7.5 Primary Analyses  
The primary endpoint , change from baseline (Day 0) compared to each treatment study visit day 
(Days 3, 7, 14 and 21) in OMI -total score , will be summarized using descriptive statistics 
(number, mean, standard deviation, minimum, maximum, median) and presented by [CONTACT_604800] m ITT populations. No inferential  statistical comparisons between groups will be 
conducted.  
                             
                                                                                           
 
 
Statistical Analysis Plan   
 
 
Sponsor: Niconovum [LOCATION_003], Inc.  
Sponsor Protocol No. 2016- NBTL -S-005  
 
 
17-May-2017  Final Version 1.0      Page 18 of 53 
7.6 Secondary  Analyses  
The primary endpoint change from baseline (Day 0) compared to each treatment study visit day 
(Days 3, 7, 14 and 21) in OMI -total score will be summarized using descriptive statistics 
(number, mean, standard deviation, minimum, maximum, median) and presented by [CONTACT_604801], HLU population, and CS population.  
The change from baseline in erythema and ulcer subscores for  each treatment study visit day 
(Days 3, 7, 14 and 21) will be summarized using descriptive statistics ( number, mean, standa rd 
deviation, minimum, maximum and median) and presented by [CONTACT_604802], PP population, HLU population , and CS population. 
No inferential  statistical comparisons between groups will be conducted.  
 
7.7 Safety Analyses  
Safety data in this study are comprised of adverse events, physical examination, vital signs  and 
clinical laboratory assessment. All safety data will be analyzed using the mITT  Population.  
 
The continuous type safety endpoints will be summarized by [CONTACT_604803] (n, mean, SD, median, minimum, maximum ) for mITT  population. The categorical type 
safety endpoints will be summariz ed by [CONTACT_604804]. No formal inferential tests will be performed on safety data.  
7.7.1  Adverse Events  
Adverse events (AEs) will be coded using the Medical Dictionary for Regulatory Activities 
(MedDR A) Coding Dictionary  version 19.1. All subjects in the mITT population will be included 
in the adverse event analysis. All adverse events will be listed chronologically by [CONTACT_3148] , 
subject and AE start date/time . This listing will include all data collected in the eCRF, along with 
the derived variable duration of AE and the coded variables system organ class (SOC) and 
preferred term (PT).  
 
Displays of AEs will include: 
• Overall Summary of AEs  
This table will include the number of events, number and percent of subjects who 
experienced AEs, serious AEs, severe AEs, related AEs and AEs leading to study 
discontinuation, summarized by  [CONTACT_3148] . 
                             
                                                                                           
 
 
Statistical Analysis Plan   
 
 
Sponsor: Niconovum [LOCATION_003], Inc.  
Sponsor Protocol No. 2016- NBTL -S-005  
 
 
17-May-2017  Final Version 1.0      Page 19 of 53 
• Summary of AEs by [CONTACT_2946], PT and Treatment  
A summary of the number of events, number and percent of subjects who experienced 
at least one AE,  as well as the number of events, number and percent of subjects who 
experienced each specific SOC, and PT will be presented by [CONTACT_3148] . If a subject has 
more than one occurrence of the same PT then the PT will be counted only once for that 
subject under  the SOC at which it was experienced.  
7.7.2  Physical Examination  
Subjects will take a complete physical examination including a review of all body systems at the 
Screening Visit.  On Day 0 visit, an assessment of general oral health by a dental professional 
will be conducted to assure compliance with relevant inclusion and exclusion criteria. Any 
abnormal findings at baseline will be recorded as medical history, and findings after baseline will 
be recorded as adverse events. No separate listing will be produced.  
 
7.7.3  Vital Signs  
Systolic (SBP), d iastolic (DBP ) blood pressure and heart rate  will be measured, for all 
scheduled study visit days (Days 0, 3, 7, 14, 21 and 24), including Screening, in a seated 
position after at least [ADDRESS_800964]. Subjects with a systolic blood pressure ≥ 150 mmHg or 
a diastolic blood pressure ≥ [ADDRESS_800965] 
summary statistics (n, mean, SD, minimum, median and maximum) for mITT  population. All 
data will  also be listed by [CONTACT_3148] , subject, visit and vital sign parameters.  
7.7.4  12-Lead Electrocardiogram  
During the Screening Visit, a standard12 -lead Electrocardiogram (ECG) will be obtained after 
the subject has rested in the supi[INVESTIGATOR_21683] [ADDRESS_800966] 30 minutes after blood sampling, if applicable. Additionally, ECG will be measured on Day 7, Day 21 and Day 24 (if follow -up is 
required).  ECG  will be summarized by [CONTACT_604805] 
(n, mean, SD, minimum, median and maximum) for the mITT  population. All data will also be 
listed by [CONTACT_3148] , subject, visit and ECG  parameters.  Overall assessment will be summarized 
using frequencies  and percentage. 
7.7.5  Clinical Laboratory  
Serum chemistry, hematology and urinalysis will be measured in all subjects at Screening, Day 0 (baseline), Day [ADDRESS_800967] will be analyzed in the clinic. The Investigator will evaluate 
                             
                                                                                           
 
 
Statistical Analysis Plan   
 
 
Sponsor: Niconovum [LOCATION_003], Inc.  
Sponsor Protocol No. 2016- NBTL -S-[ADDRESS_800968]  will be evaluated as clinically significant or not clinically significant. All 
clinically significant abnormal laboratory values that represent an unexpected change from 
Baseline will be assessed as adverse events (AEs), and an AE eCRF must be completed.  
Data in each of the three categories of hematology, chemistry and urinalysis will be listed by 
[CONTACT_3148] , subject and parameter.   
7.7.6  Recovery  
Recovery will be assessed by [CONTACT_604806] -20 total score, erythema subscore, and ulcer 
subscore at Day 24 with those at Day 21. Other safety endpoints with clinically significant 
abnormal values at Day 21 will be re- evaluated on Day 24 to assess recovery from Day 21.  
Difference between Day 21 and Day 24 in OMI -total score , erythema subscore and ulcer 
subscore  will be summarized using descriptive statistics (mean, standard deviation, minimum, 
maximum, and median) and presented by [CONTACT_604807] . No inferential  statistical comparisons between groups will be conducted.  
 
7.[ADDRESS_800969] evaluating the oral health of subjects will not be informed of the results of this pre -planned analysis prior to the completion of 
the full study analysis.   The study will continue to recruit and randomize beyond 60 subjects until 
the protocol specified 100 randomized subjects are evaluated. Also, the results of the completed study will be presented in the final report, only descriptively.    
 
                             
                                                                                           
 
 
Statistical Analysis Plan   
 
 
Sponsor: Niconovum [LOCATION_003], Inc.  
Sponsor Protocol No. 2016- NBTL -S-005  
 
 
17-May-2017  Final Version 1.0      Page 21 of 53 
8 TABLES, LISTINGS AND GRAPHS (TLGs) SHELLS  
The following TL shells are provided as a framework for the display of data from this study. The 
shells may change due to unforeseen circumstances. These shells may not be reflective of every aspect of this study but are intended to show the general layout  of the Tables and Listings 
that will be included in the final report. Table  headers,  variables  names and footnotes  will be 
modified as  need ed following  data analyses.  
Niconovum [LOCATION_003], Inc. / 2016 -NBTL -S-005                                                                                                                                                   Page 1 of X  
17-May-2017 Final Version 1.0                                                                                                                                                                                Page 22 of 53 Table 14.1.1 Disposition of Subjects  and Analysis Sets  
 
 Nicotine Polacrilex  
n (%)  Nicotine Bitartrate   
n (%)  Overall  
n (%)  
Number of  Subjects in Randomized Population  xx xx xx 
Number of Subjects in Modified  Intent -to-Treat Population  xx xx xx 
Number of Subjects in Per Protocol Population xx xx xx 
Number of  Subjects in Heavy Lozenge Use Population  xx xx xx 
Number of Subjects in Concomitant Smoker Population xx xx xx 
Number (%) of Subjects who Completed the Study xx (xx.x%)  xx (xx.x%)  xx (xx.x%)  
Number (%) of Subjects who Discontinued Early xx (xx.x%)  xx (xx.x%)  xx (xx.x%)  
Reasons for Early Discontinuation     
Adverse Event  xx (xx.x%)  xx (xx.x%)  xx (xx.x%)  
Physician Decision  xx (xx.x%)  xx (xx.x%)  xx (xx.x%)  
Protocol Deviation  xx (xx.x%)  xx (xx.x%)  xx (xx.x%)  
Sponsor ’s Decision  xx (xx.x%)  xx (xx.x%)  xx (xx.x%)  
Subject Non- compliance  xx (xx.x%)  xx (xx.x%)  xx (xx.x%)  
Withdrawal  by [CONTACT_604808] (xx.x%)  xx (xx.x%)  xx (xx.x%)  
    
 
Note:  Percentages are calculated based on the number of subjects in the Randomized Population per treatment  and overall.  
Data Source: Listing 16.2. 1 
 
     
Niconovum [LOCATION_003], Inc. / 2016 -NBTL -S-005                                                                                                                                                   Page 1 of X  
17-May-2017 Final Version 1.0                                                                                                                                                                                Page 23 of 53 Table 14.1.2  Demographics  and Baseline Characteristics  
Modified Intent -to-Treat  Population  
 Nicotine Polacrilex  
(N=xx)  Nicotine Bitartrate  
(N=xx)  Overall  
(N=xx)  
Age (years)*     
n xx xx xx 
Mean  xx.x xx.x xx.x 
SD xx.xx  xx.xx  xx.xx  
Minimum  xx xx xx 
Median  xx xx xx 
Maximum  xx xx xx 
    
Sex, n (%)     
n xx xx xx 
Male  xx (xx.x%)  xx (xx.x%)  xx (xx.x%)  
Female  xx (xx.x%)  xx (xx.x%)  xx (xx.x%)  
…    
 
Note: *Age at Informed Consent  
          Percentages are calculated based on the number of subjects in the ITT Population per treatment  and overall.  
Data Source: Listing [IP_ADDRESS], Listing [IP_ADDRESS]  
Programming Note: Table will also include race, ethnicity, height (cm), weight (kg), BMI (kg/m2) 
  
Niconovum [LOCATION_003], Inc. / [ADDRESS_800970]  Categories  Nicotine Polacrilex  
(N=xx)  Nicotine Bitartrate  
(N=xx)  Overall  
(N=xx)  
Cigarettes  Duration (Years)     
 n xx xx xx 
 Mean  xx.xxx  xx.xxx  xx.xxx  
 SD xx.xxxx  xx.xxxx  xx.xxxx  
 Minimum  xx.xx  xx.xx  xx.xx  
 Median  xx.xxx  xx.xxx  xx.xxx  
 Maximum  xx.xx  xx.xx  xx.xx  
 Cigarettes (Per Day)     
 n xx xx xx 
 Mean  xx.x xx.x xx.x 
 SD xx.xx  xx.xx  xx.xx  
 Minimum  xx xx xx 
 Median  xx.x xx.x xx.x 
 Maximum  xx xx xx 
 Frequency     
 ≥ 30 cigarettes/day  xx (xx.x%)  xx (xx.x%)  xx (xx.x%)  
 20 - 29 cigarettes/day  xx (xx.x%)  xx (xx.x%)  xx (xx.x%)  
 < 20 cigarettes/day  xx (xx.x%)  xx (xx.x%)  xx (xx.x%)  
     
 
Data Source: Listing [IP_ADDRESS]  
  
Niconovum [LOCATION_003], Inc. / 2016 -NBTL -S-005                                                                                                                                                   Page 1 of X  
17-May-2017 Final Version 1.0                                                                                                                                                                                Page 25 of 53 Table 14.2. 2.1 Summary of Change from Baseline in OMI-20 Total Score   
Modified Intent -to-Treat  Population  
 
  Treatment    
 Statistics  Nicotine Polacrilex  Nicotine Bitartrate  
Baseline  n xx xx 
 Mean  ±  SD  xx.x ± x.xx  xx.x ± x.xx  
 Median  xx.x xx.x 
 Min, Max  xx, xx  xx, xx  
Day 3   n xx xx 
 Mean  ±  SD  xx.x ± x.xx  xx.x ± x.xx  
 Median  xx.x xx.x 
 Min, Max  xx, xx  xx, xx  
Change from baseline  to Day 3  n xx xx 
 Mean  ±  SD  xx.x ± x.xx  xx.x ± x.xx  
 Median  xx.x xx.x 
 Min, Max  xx, xx  xx, xx  
Day 7   n xx xx 
 Mean  ±  SD  xx.x ± x.xx  xx.x ± x.xx  
 Median  xx.x xx.x 
 Min, Max  xx, xx  xx, xx  
    
Change from baseline  to Day 7  n xx xx 
 Mean  ±  SD  xx.x ± x.xx  xx.x ± x.xx  
 Median  xx.x xx.x 
 Min, Max  xx, xx  xx, xx  
      
      
Note: OMI – Oral Mucositis Index  
Data Source: Listing [IP_ADDRESS]  
<Programming Note: continue for  Day 14 and Day 21.> 
Niconovum [LOCATION_003], Inc. / 2016 -NBTL -S-005                                                                                                                                                   Page 1 of X  
17-May-2017 Final Version 1.0                                                                                                                                                                                Page 26 of 53 Similar tables as [IP_ADDRESS] will be generated for:  
Table [IP_ADDRESS] Summary of Change from Baseline in OMI -20 Total Score  
Per-Protocol  Population 
Table [IP_ADDRESS] Summary of Change from Baseline in OMI-20 Total Score  
Heavy Lozenge Use Population 
Table [IP_ADDRESS] Summary of Change from Baseline in OMI -20 Total Score  
Concomitant Smoker Population  
Table [IP_ADDRESS] Summary of Change from Baseline in OMI Erythema  Score  
Modified Intent -to-Treat  Population  
Table [IP_ADDRESS] Summary of Change from Baseline in OMI Erythema  Score  
Per-Protocol  Population 
Table [IP_ADDRESS] Summary of Change from Baseline in OMI Erythema  Score  
Heavy Lozenge Use Population 
Table [IP_ADDRESS] Summary of Change from Baseline in OMI Erythema  Score  
Concomitant Smoker Population  
Table [IP_ADDRESS] Summary of Change from Baseline in OMI Ulcer  Score  
Modified Intent -to-Treat  Population  
Table [IP_ADDRESS] Summary of Change from Baseline in OMI Ulcer  Score  
Per-Protocol  Population 
Table [IP_ADDRESS] Summary of Change from Baseline in OMI Ulcer  Score  
Heavy Lozenge Use Population 
Table [IP_ADDRESS] Summary of Change from Baseline in OMI Ulcer  Score  
Concomitant Smoker Population  
 
Niconovum [LOCATION_003], Inc. / 2016 -NBTL -S-005                                                                                                                                                   Page 1 of X  
17-May-2017 Final Version 1.0                                                                                                                                                                                Page 27 of 53  
  
Table [IP_ADDRESS] Overall Summary of Treatment Emergent Adverse Events (TEAEs)  
Modified Intent -to-Treat  Population  
 All Adverse Events  
 Nicotine Polacrilex  
(N=xx)  Nicotine Bitartrate   
(N=xx)  
Number (%) of Subjects with TEAE xx (xx.x%) [xx]  xx (xx.x%) [xx]  
Number (%) of Subjects with Serious TEAE xx (xx.x%) [xx]  xx (xx.x%) [xx]  
Number (%) of Subjects with Severe TEAE xx (xx.x%) [xx]  xx (xx.x%) [xx]  
Number  (%) of Subjects with Related TEAE xx (xx.x%) [xx]  xx (xx.x%) [xx]  
Number (%) of Subjects with Study Discontinued Due to TEAE xx (xx.x%) [xx]  xx (xx.x%) [xx]  
 
Note: An AE is considered to be related if it is possibly or probably related to study  processes . 
          Summaries are presented as : number of subjects , (percentage of subjects), and  [number of events] . 
Data Source: Listing 16.2.7  
  
Niconovum [LOCATION_003], Inc. / 2016 -NBTL -S-005                                                                                                                                                   Page 1 of X  
17-May-2017 Final Version 1.0                                                                                                                                                                                Page 28 of 53  
Table 14.3.1 .2 Summary of Treatment Emergent Adverse Events by [CONTACT_604809] -to-Treat  Population  
 
 All Adverse Event s 
System Organ Class/  
      Preferred Term Nicotine Polacrilex  
(N=xx)  Nicotine Bitartrate   
(N=xx)   
Any System Organ Class     
      Any Event  xx (xx.x%) [xx]  xx (xx.x%) [xx]   
Cardiac Disorders  xx (xx.x%) [xx]  xx (xx.x%) [xx]   
      Any Event  xx (xx.x%) [xx]  xx (xx.x%) [xx]   
      Bradycardia  xx (xx.x%) [xx]  xx (xx.x%) [xx]   
…    
 
Note:  All adverse events recorded throughout the study are summarized by [CONTACT_604810].  
          Summaries are presented as: number of subjects , (percentage of subjects), and  [number of events] . If multiple events occur in a category, it 
will be counted only once for calculation of frequencies at subject level.  
Data Source: Listing 16.2.7  
 
 
 
 
 
Niconovum [LOCATION_003], Inc. / 2016 -NBTL -S-005                                                                                                                                                   Page 1 of X  
17-May-2017 Final Version 1.0                                                                                                                                                                                Page 29 of 53  
Table 14.3.1 .3 Treatment -Emergent Adverse Events by [CONTACT_1196], Preferred Term and Maximum 
Relationship ( Modified Intent -to-Treat Population)  
 
  All Adverse Event s 
System Organ Class/  
      Preferred Term Maximum  
Relationship  Nicotine Polacrilex  
(N=xx)  Nicotine Bitartrate   
(N=xx)   
Any System Organ Class      
      Any Event  Unlikely  xx (xx.x% ) [xx]  xx (xx.x%) [xx]   
 Possible  xx (xx.x%) [xx]  xx (xx.x%) [xx]   
 Probably  xx (xx.x%) [xx]  xx (xx.x%) [xx]   
     
Cardiac Disorders      
      Any Event  Unlikely  xx (xx.x%) [xx]  xx (xx.x%) [xx]   
 Possible  xx (xx.x%) [xx]  xx (xx.x%) [xx]   
 Probably  xx (xx.x%) [xx]  xx (xx.x%) [xx]   
     
 
Note:  All adverse events recorded throughout the study are summarized by [CONTACT_604810].  
          Summaries are presented as: number of subjects , (percentage of subjects), and  [number of events]. If multiple events occur in a category, it 
will be counted only once for calculation of frequencies at subject level.  
Data Source: Listing 16.2.7  
 
Niconovum [LOCATION_003], Inc. / 2016 -NBTL -S-005                                                                                                                                                   Page 1 of X  
17-May-2017 Final Version 1.0                                                                                                                                                                                Page 30 of 53 Table 14.3. 4 Summary of Vital Signs  
Modified Intent -to-Treat  Population  
Parameter  (Unit)  Visit 
 Statistic  Nicotine Polacrilex  
(N=xx)  Nicotine Bitartrate  
(N=xx ) 
Systolic Blood Pressure (mmHg)  Screen ing    
  n xx xx 
  Mean  xx.x xx.x 
  SD xx.xx  xx.xx  
  Minimum  xx xx 
  Median  xx.x xx.x 
  Maximum  xx xx 
 Day 0  Baseline  …   
 Day 3  …   
…..     
 
Note:  EOS=End of Study, ET=Early Termination  
Data Source: Listing 16.2.9  
Programming Note: Parameter also includes Diastolic Blood Pressure (mmHg), Pulse Rate (bpm), Programming will continue for Day 7 , 14, 21 
and EOS.  
 
  
Niconovum [LOCATION_003], Inc. / 2016 -NBTL -S-005                                                                                                                                                   Page 1 of X  
17-May-2017 Final Version 1.0                                                                                                                                                                                Page 31 of 53  
 
Table 14.3. 5.1 Summary of  Overall ECG Interpretation   
Modified Intent -to-Treat  Population  
 
Visit   Nicotine Polacrilex  
(N=xx)  Nicotine Bitartrate  
(N=xx)  
Baseline     
 n xx xx 
 Normal, n (%)  xx (xx.x%)  xx (xx.x%)  
 Abnormal, Not Clinically Significant, n (%)  xx (xx.x%)  xx (xx.x%)  
 Abnormal, Clinically Significant, n (%)  xx (xx.x%)  xx (xx.x%)  
 …   
Day 7     
 n xx xx 
 Normal, n (%)  xx (xx.x%)  xx (xx.x%)  
 Abnormal, Not Clinically Significant, n (%)  xx (xx.x%)  xx (xx.x%)  
 Abnormal, Clinically Significant, n (%)  xx (xx.x%)  xx (xx.x%)  
    
 
Note:  EOS=End of Study  
 Data Source: Listing 16.2. 10 
Programming Note:  Programming will continue for Day 14, 21 and EOS/ET.
 
 
 
  
Niconovum [LOCATION_003], Inc. / 2016 -NBTL -S-005                                                                                                                                                   Page 1 of X  
17-May-2017 Final Version 1.0                                                                                                                                                                                Page 32 of 53 Table [IP_ADDRESS] Summary of ECG Continuous Data  
Safety Population  
ECG Parameters  
(unit)   
Visit  
Statistics  Nicotine Polacrilex  
(N=xx)  Nicotine Bitartrate  
(N=xx)  
Ventricular Rate (bpm)  Baseline*     
  n xx xx 
  Mean  xx.x xx.x 
  SD xx.xx  xx.xx  
  Minimum  xx xx 
  Median  xx.x xx.x 
  Maximum  xx xx 
 Day 7     
  n xx xx 
  mean  xx.x xx.x 
  .. xx.x xx.x 
  xx xx xx 
 …    
 
Note: *Baseline is defined as the last observation prior to the dose.  
<ECG Parameter (unit)> = Ventricular  Rate (bpm), PR Interval (msec), QRS Duration (msec), QT Interval (msec), QTcB Interval (msec)  
Programming Note: Table also includes Day 14, 21 and EOS/ET.  
  
Niconovum [LOCATION_003], Inc. / 2016 -NBTL -S-005                                                                                                                                                   Page 1 of X  
17-May-2017 Final Version 1.0                                                                                                                                                                                Page 33 of 53 Table 14.3 .6.1 Summary of Breath carbon monoxide (CO) levels  (mITT Population)  
 
   Treatment    
Visit  Statistics  Nicotine Polacrilex  Nicotine Bitartrate  
Day 3  Average  CO level (Compliant)  n xx xx 
  Mean  ±  SD  xx.x ± x.xx  xx.x ± x.xx  
  Median  xx.x xx.x 
  Min, Max  xx, xx  xx, xx  
     
 CO level <=10pmm or not?  n (%)    
 Yes  xx (xx.x%)  xx (xx.x%)  
 No  xx (xx.x%)  xx (xx.x%)  
     
Day 7      
Day 14        
Day 21        
       
Data Source: Listing 16.2.5 .1 
  
Niconovum [LOCATION_003], Inc. / 2016 -NBTL -S-005                                                                                                                                                   Page 1 of X  
17-May-2017 Final Version 1.0                                                                                                                                                                                Page 34 of 53 Table 14.3 .6.2 Summary of Study Drug Administration  
 
   Treatment    
Population   Statistics  Nicotine Polacrilex  Nicotine Bitartrate  
mITT  mITT Average  number of 
used lozenges per day  n xx xx 
  Mean  ±  SD  xx.x ± x.xx  xx.x ± x.xx  
  Median  xx.x xx.x 
  Min, Max  xx, xx  xx, xx  
     
 Number of non -compliance 
days>2 or not  n (%)    
 Yes  xx (xx.x%)  xx (xx.x%)  
 No  xx (xx.x%)  xx (xx.x%)  
     
     
PP     
HLU     
     
       
Data Source: Listing [IP_ADDRESS]  
  
Niconovum [LOCATION_003], Inc. / 2016 -NBTL -S-005                                                                                                                                                   Page 1 of X  
17-May-2017 Final Version 1.0                                                                                                                                                                                Page 35 of 53 Table 14.3 .6.3 Summary of Medication  Compliance (mITT Population)  
 
  Treatment   
Compliance  Nicotine Polacrilex  n (%)  Nicotine Bitartrate  n (%)  
   
   
Yes xx (xx.x%)  xx (xx.x%)  
No xx (xx.x%)  xx (xx.x%)  
   
     
Data Source: Listing 16.2.5 .1 & Listing [IP_ADDRESS]  
  
Niconovum [LOCATION_003], Inc. / 2016 -NBTL -S-005                                                                                                                                                   Page 1 of X  
17-May-2017 Final Version 1.0                                                                                                                                                                                Page 36 of 53 Table 14.3 .7.1 Summary of difference in OMI -20 Total Score Between Day 21 and Day 24  
 
   Treatment    
Population   Statistics  Nicotine Polacrilex  Nicotine Bitartrate  
mITT  Day 21   n xx xx 
  Mean  ±  SD  xx.x ± x.xx  xx.x ± x.xx  
  Median  xx.x xx.x 
  Min, Max  xx, xx  xx, xx  
 Day 24   n xx xx 
  Mean  ±  SD  xx.x ± x.xx  xx.x ± x.xx  
  Median  xx.x xx.x 
  Min, Max  xx, xx  xx, xx  
 Difference between Day 21 
  n xx xx 
  Mean  ±  SD  xx.x ± x.xx  xx.x ± x.xx  
  Median  xx.x xx.x 
  Min, Max  xx, xx  xx, xx  
     
PP     
     
HLU       
       
       
Note: OMI – Oral Mucositis Index  
Data Source: Listing [IP_ADDRESS]  
  
Niconovum [LOCATION_003], Inc. / 2016 -NBTL -S-005                                                                                                                                                   Page 1 of X  
17-May-2017 Final Version 1.0                                                                                                                                                                                Page 37 of 53 Similar tables a s [IP_ADDRESS] will be generated for:  
 
Table 14.3 .7.2 Summary of difference in OMI  Erythema  Score Between  Day 21 and Day 24 
Modified Intent -to-Treat  Population  
Table 14.3 .7.3 Summary of difference in OMI  Ulcer Score Between Day 21 and Day 24 
Modified Intent -to-Treat  Population  
  
Niconovum [LOCATION_003], Inc. / [ADDRESS_800971]  Treatment  Age*  
(years)  Gender  Date of Informed Consent  Date of Enrollment  Smoking category  
xxxxx  Nicotine 
Polacrilex  xx Male  DDMONYYYY  DDMONYYYY  Type 1  
……       
 
Note: *Age at informed consent .  
          Type 1: # of smoked cigarette per day < 20; Type 2: 20- 29; Type 3: >=30.  
 
 
 
 
 
  
 
 
 
 
 
Niconovum [LOCATION_003], Inc. / [ADDRESS_800972] Disposition and Completion/Early Termination 
 
Treatment  Subject  Date of Study Completion 
or Early Discontinuation Date of Last Contact  [CONTACT_604811]*  
Nicotine 
Polacrilex  xxxx DDMONYYYY  DDMONYYYY  No xxxxxxxxxxx  
 ……     
……      
 
Note: *A corresponding AE number will be displayed if Reason for Discontinuation or Reason for Study Discontinuation is “Adverse Event”.  
 
  
Niconovum [LOCATION_003], Inc. / [ADDRESS_800973]  Deviation  Start 
Date  Visit Protocol Deviation 
Type  Description of Protocol Deviation  
Nicotine 
Polacrilex  xxxx DDMONYYYY  xxxx Xxxxx  Xxxxxxx  
 ……     
….      
 
 
  
Niconovum [LOCATION_003], Inc. / [ADDRESS_800974]  Informed 
Consent D ate Gender  Date of Birth  Age*  
(years)  Race  Ethnicity  Height  
(cm) Weight  
(kg) BMI 
(kg/m2) 
Nicotine 
Polacrilex  xxxx DDMONYYYY  x DDMONYY
YY xx xxxxx  xxxxx  xxx xx xx 
 ……          
…           
 
Note: *Age at Informed Consent . 
 
 
 
 
 
  
 
 
 
 
Niconovum [LOCATION_003], Inc. / 2016 -NBTL -S-005                                                                                                                                                   Page 1 of X  
17-May-2017 Final Version 1.0                                                                                                                                                                                Page 42 of 53 Listing [IP_ADDRESS]  Urine  Drug Screen and Alcohol Breath Test  
 
 
Treatment   
Subject   
Visit Collection 
Date  Ampheta  
-mines  Barbitur  
-ates Benzodia  
-zepi[INVESTIGATOR_604780]  
-binoids   
Cocaine   
Opi[INVESTIGATOR_604781] 0  ….        
     …..          
……           
 
 
  
Niconovum [LOCATION_003], Inc. / [ADDRESS_800975]  MH #  Medical History C ategory  Medical History Term  Start Date and Time  End Date  and Time  
Nicotine 
Polacrilex  xxxx x  Xxxxxx  DDMONYYYY  DDMONYYYY  
  x  Xxxxxx  DDMONYYYY  Ongoing  
 ……      
……       
 
Note: MH=Medical History  (including relevant medical [within last 5 years]) . 
 
                
Niconovum [LOCATION_003], Inc. / [ADDRESS_800976]  MH # Medication Name  [CONTACT_50726]/Unit/Frequency  
/Route  Start Date/Stop Date  Indication/  
Administered for 
AE or MH?  
Nicotine 
Polacrilex  xxxx x xxxxxxxxx  20/ mg/ Once/ Oral  DDMONYYYY HH:MM  / 
 DDMONYYYY HH:MM  Headache/  
Yes (AE # 4)  
  x xxxxxxxxx  xxx/ xxx/ xxxx/xxxx DDMONYYYY HH:MM  / 
Ongoing  xxxxx/  
No 
 ……      
……       
 
 
 
  
Niconovum [LOCATION_003], Inc. / [ADDRESS_800977]  Collection Date and Time Hepatitis B Surface Antigen  Hepatitis C Virus Antibody  HIV Antibody  
Nicotine 
Polacrilex  xxxx DDMONYYYY HH:MM  Negative  Negative  Non- Reactive  
 ……     
……      
 
 
 
                  
Niconovum [LOCATION_003], Inc. / [ADDRESS_800978]  Visit Collection Date and Time  Results  
Nicotine 
Polacrilex  xxxx Screening  DDMONYYYY   HH:MM  Negative  
  Day 0  DDMONYYYY  HH:MM  Negative  
     
 ……     
……      
 
Note: Serum pregnancy test at Screening; urine pregnancy test at Check -in of Day [ADDRESS_800979] Visit.  
 
 
  
Niconovum [LOCATION_003], Inc. / [ADDRESS_800980]  Substance  Start Date of 
Substance Used  End Date of 
Substance Used  Substance 
Use 
Ongoing?  Frequency 
of Use Amount/  
Unit/ 
Frequency  Typi[INVESTIGATOR_604782]  20JAN1990   Yes Daily  10/Cigarette/Per Day  xxxx 
 ……        
 xxxx Cigarettes  01JUL2005  01AUG2015  No Daily  15/Cigarette/Per Day  xxxx 
         
 ……        
……         
 
  
Niconovum [LOCATION_003], Inc. / 2016 -NBTL -S-005                                                                                                                                                   Page 1 of X  
17-May-2017 Final Version 1.0                                                                                                                                                                                Page 48 of 53 Listing [IP_ADDRESS] Study Drug Administration  
 
Treatment  Subject  Visit Dispense/  
Admi nistration 
Date  Number of  
Dispensed  Number of 
Returned  Number of  
Daily Use  Compliance  
Flag* Number of  
Non- Compliance 
Days  
Nicotine 
Polacrilex  xxxx Day 0  DDMONYYYY  xx     
  Day 1  DDMONYYYY    xx Yes  
  Day 7  DDMONYYYY  xx xx xx No  
  ….       
  Day 21  DDMONYYYY    xx Yes  
  Day 24  DDMONYYYY   xx   xx 
 xxxx Day 0        
  ….       
  ….       
         
 
Note:  Drug dispense happens on Day 0, 7 and 14; Drug return happens on Day 7, 14 and 24.  
          *Compliance will be flagged ‘No’ for daily lozenge  use fewer than 9 or more than 20.  
  
Niconovum [LOCATION_003], Inc. / [ADDRESS_800981]  Visit  Collection Date  CO Level (ppm)  Compliance Flag  Total Number of  
Non- Compliance 
Days  
Nicotine 
Polacrilex  xxxx Day 0   DDMONYYYY   xxx   
  Day 3       
 …… Day 7     
……  Day 21    xx 
      
 
Note: CO = Carbon Monoxide; CO levels exceeding 10 ppm  during treatment will be flagged as ‘No’;  
          CO level should be higher than 10 ppm on Day 0. CO level will be measured on Day 0, 3, 7, 14 and 21 . 
 
  
Niconovum [LOCATION_003], Inc. / 2016 -NBTL -S-005                                                                                                                                                   Page 1 of X  
17-May-2017 Final Version 1.0                                                                                                                                                                                Page 50 of 53  
Listing [IP_ADDRESS] Oral Mucositis Index  (OMI -20) 
 
Treatment  Subject  Visit Collection Date  Organ  Location  Atrophy  Erythema Edema Ulcer  
/Pseudomembrane 
Nicotine 
Polacrilex  xxxx  DDMONYYYY  Labial Mucosa  Lower   xx  xx 
     Upper   xx  xx 
 xxxx  DDMONYYYY  Buccal  Mucosa  Right   xx  xx 
     Left  xx  xx 
 ……   Tongue Dorsal  xx xx  xx 
     Lateral   xx xx xx 
     Ventral   xx  xx 
    Mouth Floor    xx  xx 
    Soft Palate    xx  xx 
          
          
          
……          
 
 
 
Niconovum [LOCATION_003], Inc. / [ADDRESS_800982] Visit AE #  Treatment 
Emergent?  System Organ Class/  
Preferred Term/  
Verbatim Term  Start Date and Time/  
Stop Date and Time/  Duration 
(DD:HH:M
M)* Severity/ 
Serious/  
Relationship to 
study  Outcome Action 
Taken / 
Other 
Action  Caused 
Study  
Discontin  
-uation 
Nicotin
e 
Polacril
ex xxxx Day 1  x Yes Nervous system disorders/ Headache/ 
Headache DDMONYYYY 
HH:MM/ /  Ongoing  
  Mild/ Yes (Death)/ 
Unrelated/  Recovered/
Resolved None/None No 
   x Yes Gastrointestinal 
disorders/ Vomiting/ Vomiting  DDMONYYYY HH:MM / 
DDMONYYYY HH:MM  DD:HH:MM  Moderate/ No/ Related /  Recovered/Resolved None/None No 
 ……           
……            
 
Note:  *DD:  HH: MM = Days:  Hours:  Minutes . 
 
Programming Note:  1) if the status of the adverse event is ongoing at the end of the study (i.e. AEONGO=”Y” and AEENDTC is missing), the “Stop 
Date and Time” will be presented as “Ongoing” ; 2) if any seriou s adverse event (SAE) occurs, a similar listing will be produced for S AEs 
separately.  
 
 
         
Niconovum [LOCATION_003], Inc. / 2016 -NBTL -S-005                                                                                                                                                   Page 1 of X  
17-May-2017 Final Version 1.0                                                                                                                                                                                Page 52 of 53  
Listing 16.2.8.X Laboratory Measurements: <Laboratory Panel>  
Full Analysis Set  Population 
 
Treatment  Subject  Test 
Performed? Date of Sample 
Collection  Lab Test (Unit)  Value  Reference 
Range 
Indicator  Normal 
Range  Clinically 
Significant?  
 xxxx Yes DDMONYYYY  xxxxxx(xxxx)  xx High xx - xxx No 
    xxxxx (xxxx)  xx Abnormal  Negative   
    ……     
 xxxx No       
 ……        
……         
 
 
Programming Note:  < Laboratory Panel> = Hematology, Chemistry, Urinalysis. X will be assigned as 1,  2, and 3 for each laboratory panel, and 
each listing will continue for all parameters (unit) in that panel.  
 
           
Niconovum [LOCATION_003], Inc. / [ADDRESS_800983]  Visit Collection Date 
and Time Position  SBP 
(mmHg) DBP 
(mmHg) HR 
(bpm)  
 xxxx Screening  DDMONYYYY 
HH::MM  Sitting  xxx xx xx 
  Day 0  DDMONYYYY   xxx xx xx 
        
 ……       
……        
 
Note: SBP=Systolic Blood Pressure,  DBP=Diastolic Blood Pressure, H R=Heart Rate. 
         EOS = End of Study, ET = Early Termination.  
 
Programming Note:  The table will continue on Day 3, 7, 14, 21 and EOS.  
 
 
 